J Affect Disord
May 16, 2026
David S. Mathai, Madeleine Cluck, Amna M. Aslam et al.
1 citation
Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3).
Psychedelics
May 1, 2026
Madeleine Cluck, Alison B. Purcell, Zuzana Kazan et al.
There is currently an ongoing resurgence in research on the therapeutic potential of psychedelics for psychiatric conditions. Psychedelic-assisted therapy (PAT) differs from most current forms of psychiatric treatment in two primary domains: its requirement for fewer doses (often just one), and its documented ability to promote profound insights, introspection, and cognitive shifts. Autism...
JAMA Netw Open
January 2, 2026
Amy L. Mcguire, Logan Neitzke-Spruill, Jill O. Robinson et al.
4 citations
Importance: The availability of psychedelic retreats has grown to meet the demand for access to these substances. Despite centuries of use among Indigenous communities, psychedelics can pose serious risks for some users. Objective: To determine safety precautions that retreat organizations that offer psychedelic substances currently use. Design, Setting, and Participants: This qualitative study...
Translational Behavioral Medicine
2026
Joshua Mitchell, Logan Neitzke-Spruill, David S. Mathai et al.
1 citation
BACKGROUND: Psychedelics such as 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin are showing promising results in clinical trials for the treatment of mental health disorders, including post-traumatic stress disorder, addiction, and treatment-resistant depression. US Food and Drug Administration approval may be on the horizon. Yet, little is known about how these treatments will move...
PLoS One
May 2, 2025
Nikita Singh, Srijith Kambala, Logan Neitzke-Spruill et al.
10 citations
Research into psychedelics’ clinical potential has corresponded to a growth in public interest and adult use. One common pathway to accessing psychedelics is through psychedelic retreats. While individual retreats have been characterized in the anthropological literature, no systematic evaluation of the psychedelic retreat industry exists. Assessing the characteristics of the psychedelic...
Journal of Drug Issues
April 26, 2025
Shayla Frinton, Jill O. Robinson
Motives are a highly influential force in substance use and vary depending on the substance or dose being used. Little research has compared motives across different doses of psilocybin. Psilocybin is often ingested in microdoses (0.1–0.4 g) or macrodoses (1 g+), each producing unique perceptual and mood effects. The current study examined whether motives for microdose and macrodose psilocybin...
Brazilian Journal of Psychiatry
2025
David S. Mathai, Jill O. Robinson, Kevin Wagner et al.
1 citation
OBJECTIVE: Despite growing research on the potential mental health benefits of psychedelics, there has been limited study of these drugs in populations with obsessive-compulsive disorder (OCD) and with Hispanic and Latin American (H/L) ancestry. METHODS: Demographic and clinical assessments were conducted as part of the Latin American Trans-ancestry Initiative for OCD genomics (LATINO) Study in...
Neuroethics
June 20, 2024
Logan Neitzke-Spruill, Caroline Beit, Jill O. Robinson et al.
26 citations
Psychedelic experiences are often compared to “transformative experiences” due to their potential to change how people think and behave. This study empirically examines whether psychedelic experiences constitute transformative experiences. Given psychedelics’ prospective applications as treatments for mental health disorders, this study also explores neuroethical issues raised by the...